(Total Views: 99)
Posted On: 11/13/2024 4:02:20 PM
Post# of 154
NetworkNewsBreaks – Clene Inc. (NASDAQ: CLNN) Reports Q3 2024 Results and Progress on ALS Treatment Pathway
Clene (NASDAQ: CLNN) reported its Q3 2024 financial results and provided updates on its CNM-Au8 programs. Key operational highlights included a recent FDA meeting to discuss the potential for accelerated approval of CNM-Au8 for ALS, a 1-for-20 reverse stock split to meet Nasdaq requirements, an amended debt facility extending funding into Q2 2025, and a $7.3 million funding round. Clene’s Phase 3 RESTORE-ALS trial was presented in October, showcasing the company’s commitment to ALS treatment innovation. Financially, Clene ended Q3 with $14.6 million in cash and reported an $8.0 million net loss, reflecting decreased R&D and G&A expenses, but lower gains on warrant liability adjustments compared to 2023.
NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://nnw.fm/CLNN
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Clene (NASDAQ: CLNN) reported its Q3 2024 financial results and provided updates on its CNM-Au8 programs. Key operational highlights included a recent FDA meeting to discuss the potential for accelerated approval of CNM-Au8 for ALS, a 1-for-20 reverse stock split to meet Nasdaq requirements, an amended debt facility extending funding into Q2 2025, and a $7.3 million funding round. Clene’s Phase 3 RESTORE-ALS trial was presented in October, showcasing the company’s commitment to ALS treatment innovation. Financially, Clene ended Q3 with $14.6 million in cash and reported an $8.0 million net loss, reflecting decreased R&D and G&A expenses, but lower gains on warrant liability adjustments compared to 2023.
NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://nnw.fm/CLNN
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)
